William B. Donnellan

Oncology

250 25th Ave N
Ste 412
Nashville, TN 37203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.

Operationalization and Use of Bispecific T-Cell-Engaging Antibodies in Community Practices: Multidisciplinary Perspectives on Developing Logistics and Workflow for Cytokine Release Syndrome Management.

Journal: Journal of the advanced practitioner in oncology

Published: August 07, 2025

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Journal: Blood advances

Published: April 07, 2025

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.

Journal: Hematological oncology

Published: January 31, 2024

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Journal: Clinical and translational science

Published: October 24, 2023

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.

Journal: Clinical hematology international

Published: May 24, 2023

Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.

Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experience from a predominantly US community setting.

Journal: Cancer medicine

Published: April 26, 2023

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 20, 2023

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.

Journal: Clinical and translational science

Published: July 06, 2022

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 10, 2022

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.

Journal: The oncologist

Published: February 03, 2022

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.

The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: November 24, 2021

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.

Journal: Blood advances

Published: May 13, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026